Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan presented as a 20 mg nasal spray for nasal use. It is indicated for the acute treatment of migraine attacks, with or without aura, providing rapid relief of headache pain and associated symptoms in adult patients.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products that meet European Union regulatory standards.

Sumatriptan acts on the serotonergic pathway to provide acute migraine relief.

- Migraine with aura: rapid reduction of headache intensity and associated symptoms. - Migraine without aura: alleviates pain and photophobia when taken at onset. - Acute migraine attacks in adults: provides fast‑acting relief for single or multiple episodes as directed by a physician.

Imigran may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Taste disturbance: altered or unpleasant taste sensation. - Nasal irritation: burning or stinging in the nasal passages. - Nausea: feeling of sickness or urge to vomit. - Dizziness: light‑headed or unsteady feeling. - Somnolence: mild drowsiness or fatigue. - Paresthesia: tingling sensations, often in the face or extremities.

Serious or Rare Side Effects: - Chest discomfort or tightness: possible cardiac ischemia. - Coronary vasospasm: severe constriction of heart vessels. - Severe hypertension: sudden increase in blood pressure. - Serotonin syndrome: potentially life‑threatening condition when combined with other serotonergic agents. - Allergic reactions: rash, itching, swelling, or anaphylaxis.

Before prescribing Imigran, clinicians should consider several safety factors to minimize risk.

- Cardiovascular disease: contraindicated in patients with coronary artery disease, uncontrolled hypertension, or peripheral vascular disease. - Hemiplegic or basilar migraine: avoid use due to potential cerebrovascular complications. - Concomitant serotonergic agents: assess risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors. - Pregnancy and lactation: use only if benefit outweighs potential risk; safety data are limited. - Storage at room temperature: keep below 25 °C in original packaging, protect from moisture and light.

Sumatriptan can interact with several medication classes, requiring careful review of a patient’s drug regimen.

Major Interactions (Avoid): - MAO inhibitors: increase risk of serotonin syndrome; avoid concurrent use. - Other triptans or ergot derivatives: additive vasoconstrictive effects may cause serious cardiovascular events. - SSRIs, SNRIs, or other serotonergic drugs: heightened potential for serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise sumatriptan plasma levels, increasing adverse effect risk.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: sumatriptan may enhance blood‑pressure‑lowering effects; monitor blood pressure. - Oral contraceptives: may slightly increase migraine frequency; observe clinical response. - Antihistamines or sedatives: may augment dizziness or somnolence; adjust dosage if needed.